+、CD4+、CD3+和CD4+/CD8+水平均明顯高于治療前和對照組,差異均有統(tǒng)計學(xué)意義(P<0.05);對照組治療前后比較差異無統(tǒng)計學(xué)意義。觀察組白細(xì)胞下降、惡心嘔吐、血小板下降的發(fā)生率明顯低于對照組(P<0.05),兩組肝、腎功能異常率相比無明顯的差異。結(jié)論 艾迪注射液聯(lián)合埃克替尼對非小細(xì)胞肺癌的效果較佳,能改善其CD細(xì)胞亞群水平和生活質(zhì)量,減輕不良反應(yīng)。;Objective To study the clinical effect of Aidi Injection combined with icotinib in treatment of non-small cell lung cancer. Methods Selected 84 cases of patients with non-small cell lung cancer from June 2015 to June 2018, divided into two groups randomly, and each group had 42 cases. The control group was treated with Icotinib Hydrochloride Tablets, 125 mg/time, three times daily. While the observation group was treated with Icotinib Hydrochloride Tablets combined with Aidi Injection, 50 mL/time, once daily. One course of treatment was 3 weeks, all of them were treated for 3 courses. The improvement rate of quality of life, the level of T cell subsets, and adverse reactions were compared between two groups. Results After treatment, the effective rate of the observation group was 69.05%, which was significantly higher than 69.05% in the control group (P<0.05). After treatment, the improvement rate of quality of life in the observation group was 61.90%, which was significantly higher than 33.33% in the control group (P<0.05). After treatment, the level of CD8+, CD4+, CD3+, and CD4+/CD8+ in the observation group after treatment was significantly higher than that before treatment and control group (P<0.05). There was no significant difference before and after treatment in the control group. The incidence of leukopenia, nausea, vomiting and thrombocytopenia in the observation group was significantly lower than control group (P<0.05). There was no significant difference in the abnormal rate of liver and kidney function between two groups. Conclusion Aidi Injection combined with Icotinib Hydrochloride Tablets has better effect on nonsmall cell lung cancer, can improve the level of T cell subsets and quality of life, and reduce adverse reactions."/>